Neurotez, Inc. Announces Grant of U.S. Patent 8,227,408 Around Its Leptin Therapy for Alzheimer’s Disease  
7/27/2012 10:06:49 AM

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Neurotez, Inc. today announced the grant of U.S. Patent number 8,227,408 by the United States Patent and Trademark Office covering the company’s lead product candidate, Leptin. The patent protects use of the hormone Leptin for treating a progressive cognitive disease, disorder or condition, such as Alzheimer's disease (AD), resulting from accumulation of an amyloid peptide or for improving resilience of cognitive function by modulating the accumulation of the amyloid peptide in brain.